[HTML][HTML] Heart failure with mildly reduced and preserved ejection fraction: A review of disease burden and remaining unmet medical needs within a new treatment …

N Desai, E Olewinska, A Famulska, C Remuzat… - Heart Failure …, 2024 - Springer
This review provides a comprehensive overview of heart failure with mildly reduced and
preserved ejection fraction (HFmrEF/HFpEF), including its definition, diagnosis, and …

Role of splanchnic circulation in the pathogenesis of heart failure: State-of-the-art review

H Yaku, M Fudim, SJ Shah - Journal of Cardiology, 2024 - Elsevier
A hallmark of heart failure (HF), whether it presents itself during rest or periods of physical
exertion, is the excessive elevation of intracardiac filling pressures at rest or with exercise …

Myocardial Injury by COVID-19 Infection Assessed by Cardiovascular Magnetic Resonance Imaging―A Prospective Multicenter Study―

S Kato, T Kitai, D Utsunomiya, M Azuma, K Fukui… - Circulation …, 2024 - jstage.jst.go.jp
Background: This prospective multicenter study assessed the prevalence of myocardial
injury in patients with COVID-19 using cardiac magnetic resonance imaging (CMR) …

Empagliflozin cost‐effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction

H Tsutsui, H Sakamaki, S Momomura… - ESC Heart …, 2024 - Wiley Online Library
Aims Empagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, was shown to be effective
in patients with heart failure with preserved ejection fraction (HFpEF) in the EMPEROR …

Pulmonary pressure-flow responses to exercise in heart failure treated with angiotensin receptor neprilysin inhibitor

N Yamaguchi, Y Hirata, S Nishio, T Takahashi… - International Journal of …, 2024 - Elsevier
Background The role of the angiotensin receptor neprilysin inhibitor (ARNI) in cardiac
function, particularly its impact on pulmonary circulation, remains underexplored. Recent …

[HTML][HTML] Initiation and continuation of pharmacological therapies in patients hospitalized for heart failure in Japan

S Okami, C Lecomte, H Raad, M Aguila, Z Mohrova… - Scientific Reports, 2024 - nature.com
Currently, the utilization patterns of medications for heart failure (HF) after worsening HF
events remain unelucidated in Japan. Here, we conducted a retrospective cohort study …

Two-year clinical outcome of MitraClip transcatheter edge-to-edge repair from the J-MITRA Registry Data

T Imamura, M Nakai, Y Iwanaga, Y Sumita, M Tao… - Circulation …, 2024 - jstage.jst.go.jp
Background: The introduction of transcatheter edge-to-edge repair for moderate-to-severe or
severe mitral regurgitation (MR) utilizing the MitraClip system became reimbursed and …

[HTML][HTML] Xanthine oxidase inhibitors treatment or discontinuation effects on mortality: evidence of xanthine oxidase inhibitors withdrawal syndrome

M Kuwabara, M Nakai, Y Sumita, Y Iwanaga… - Frontiers in …, 2024 - frontiersin.org
Objectives: This study investigates the impact of xanthine oxidase inhibitors (XOI) on
mortality in patients with cardiovascular diseases. XOI withdrawal has been reported to …

[HTML][HTML] Lower doses of carvedilol in Japanese heart failure patients with reduced ejection fraction could show the potential to be non-inferior to higher doses in US …

M Maeda, D Humber, E Hida, T Ohtani, G Wang, T Wu… - Plos one, 2024 - journals.plos.org
The Japanese national guidelines recommend significantly lower doses of carvedilol for
heart failure with reduced ejection fraction (HFrEF) management than the US guidelines …

[HTML][HTML] Establishment of in-hospital nutrition support program for middle-aged and elderly patients with acute decompendated heart failure

Y Li, F Zhu, D Ren, J Tong, Q Xu, M Zhong… - BMC Cardiovascular …, 2024 - Springer
Objective To construct a nutrition support program for middle-aged and elderly patients with
acute decompensated heart failure (ADHF) during hospitalization. Methods Based on the …